New York, NY -- (SBWIRE) -- 10/05/2013 -- StockMarketIntel.com issues a special report on the following stocks: Forest Oil Corporation(NYSE:FST), EMC Corporation(NYSE:EMC), Galena Biopharma Inc(NASDAQ:GALE), MannKind Corporation(NASDAQ:MNKD)
Forest Oil Corporation(NYSE:FST) recently declined -9.61%, while trading on 18.03 million shares at the price of $5.74. If we look at its trading history of the past 52 weeks, the share price suffered a low of $3.77 and was moved to its maximum level of $9.12.The stock changed hands in a range of $5.71 to $6.52, bringing its market capitalization at about $689.25 million. Forest Oil Corporation (Forest) is an independent oil and gas company engaged in the acquisition, exploration, development, and production of oil, natural gas, and natural gas liquids in North America.
Has FST Found The Bottom and Ready To Move Up? Find Out Here
EMC Corporation(NYSE:EMC) gained +1.07 % recently, in the current trading session, at $25.43 with a total volume of 33.22 million shares. The stock, on average, trades on a volume of 14.47 million shares. It floated in a range of $25.04 to $25.45 during the recent trading session, with a beta value of 0.90. Its market capitalization now moved to about $52.92 billion. In the past 52 weeks, the share price has not declined below $21.45 or above $27.59. EMC Corporation (EMC), and its subsidiaries develop, deliver and support the Information Technology (IT) industry’s range of information infrastructure and virtual infrastructure technologies, solutions and services.
For How Long EMC’s Gloss will Attract Investors ? Find out via this report
Galena Biopharma Inc(NASDAQ:GALE) recently declined -4.18% and was moving within a range of $2.21-$2.42, its current trading price is $2.29. The stock is moving up till now with a total volume of 3.12 million shares, versus an average volume of 3.55 million shares. The share price hit its 52-week low of $1.23 and $3.00 was the best price. Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.
Why Should Investors Buy GALE After the Recent Fall? Just Go Here and Find Out
MannKind Corporation(NASDAQ:MNKD) declined -4.10% in its current trading activity, bringing its market capitalization around $1.62 billion. The total number of shares that changed hands during the current session up till now was 4.99 million shares, as compared to average trading volume of 5.28 million shares. The share price after opening at $5.64 made a high of $5.67 and hovered above $5.37, while its recent trading price was $5.38. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.
Will MNKD Get Buyers Even After The Recent Rally? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)